Complete Atrioventricular Septal Defect Repair in Patients With Down Syndrome Presenting Beyond Six Months- A Single
Kartik Patel1, Chandrasekaran Ananthanarayanan1, Trushar Gajjar1
1Department of Cardiovascular and Thoracic Surgery, U. N. Mehta Institute of Cardiology and Research Centre, Ahmedabad, India.
Insights
Complete atrioventricular septal defect repair in Down syndrome patients over six months old is feasible. Despite early mortality risks, long-term survival is 85%, with careful monitoring for valve issues crucial.
Area of Science:
- Cardiology
- Pediatric Surgery
- Genetics
Background:
- Complete atrioventricular septal defect (cAVSD) is the most common cardiac defect in Down syndrome (DS).
- Early surgical repair (before 6 months) is recommended to prevent pulmonary artery hypertension (PAH).
- Delayed repair is common in developing countries, necessitating outcome analysis.
Purpose of the Study:
- To retrospectively analyze the outcomes of biventricular repair for cAVSD in DS patients presenting after six months of age.
- To identify risk factors for mortality and reoperation in this cohort.
- To evaluate long-term survival and clinical status post-repair.
Main Methods:
- Retrospective review of 60 DS patients with cAVSD undergoing biventricular repair (2015-2019) after 6 months of age.
- Comparison with 42 DS patients repaired before 6 months.
- Analysis of laboratory parameters, echocardiographic data, clinical findings, and follow-up results.
Main Results:
- Median age at repair was 8 months; 11.7% early mortality (n=7) due to RV dysfunction/PAH and sepsis.
- Independent risk factors for mortality included right AVVR grade, postoperative bilirubin, and creatinine.
- Mean follow-up was 1658 days, with an 85% survival rate at 1, 5, and 10 years; late reoperation rate was 5.6%.
Conclusions:
- Surgical repair of cAVSD in late-presenting DS patients is feasible with good long-term outcomes.
- Close follow-up is essential to monitor for potential late development of right atrioventricular valve regurgitation (AVVR).
- Patients remain asymptomatic with no residual severe PAH at long-term follow-up.
Abstract:
BackgroundComplete atrioventricular septal defect (cAVSD) is the most common cardiac lesions associated with Down syndrome (DS). In DS, cAVSD repair is ideally performed before six months of age to prevent irreversible pulmonary artery hypertension (PAH). However, in developing countries, delayed repair is often unavoidable. We retrospectively analyzed the outcomes of cAVSD repair in DS patients presenting beyond six months of age.MethodBetween 2015 and 2019, 60 DS patients with cAVSD who underwent biventricular repair were reviewed. During the same time period 42 DS patients under 6 months of age underwent cAVSD repair. Their laboratory parameters and echocardiographic data were analyzed. Clinical findings as well as echocardiographic results at last follow-up were recorded.ResultMedian age of the cohort was eight months. There were 7/60 (11.7%) early mortalities due to right ventricular dysfunction secondary to persistent PAH (n = 4) and sepsis (n = 3). We found that right atrioventricular valve regurgitation (AVVR) grade (OR = 5.7, P = .017), postoperative serum bilirubin (OR = 4.03, P = .04), postoperative creatinine (OR = 7.06, P = .008), and right AVVR Gmax (OR = 6.08, P = .009) were independent risk factors for mortality. Mean follow-up was 1658 ± 771 days with a survival rate of 85% at 1, 5, and 10 years. Late reoperation (5.6% vs 3.7%) as well as prevalence of more than mild regurgitation was higher for the right AV valve as compared with the left AV valve (11.5% vs 1.9%). We did not find any factors associated with reoperation. All patients were clinically asymptomatic and did not have residual severe PAH.ConclusionComplete Atrioventricular septal defect repair in late-presenting patients with DS is feasible and yields good long-term outcomes. However, close follow-up is necessary to monitor for the late development of right AVVR.
More Related Videos
Related Concept Videos
Mitral Stenosis I: Introduction
Mitral Stenosis III: Medical Management
Cardiomyopathy V: Interprofessional Care


